Clinical trials
Colorectal Cancer (MSI-H) clinical trials
Below are recruiting colorectal cancer (msi-h) clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT04547166RecruitingPhase 2/Phase 3
New targeted immune drug plus bevacizumab and chemo for colon cancer
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
Guangzhou, GuangdongAges 18–75 - NCT05991102Recruiting
Radiofrequency treatment with Lonsurf and Avastin for advanced colorectal cancer
This trial tests if adding a special radiofrequency treatment to the drugs Lonsurf (TAS-102) and Avastin (bevacizumab) can help people whose colorectal cancer has spread to the liver and has not responded to previous treatments. It is for patients with limited options who have already tried at least two standard chemotherapy regimens.
BerlinAges 18 years+ - NCT06149481RecruitingPhase 1/Phase 2
STAR15 immunotherapy for metastatic colorectal cancer
This trial tests a combination of four drugs (SX-682, TriAdeno vaccine, retifanlimab, and N-803) to see if they can help people with colorectal cancer that has spread. It may be an option if you have already tried at least two standard treatments or cannot take them.
Bethesda, MarylandAges 18–120 - NCT07150247RecruitingPhase 2
Study of IB-FOLFIRI for advanced colon cancer with BRAF V600E mutation
This trial tests a new combination of drugs (IB-FOLFIRI) for people with metastatic colorectal cancer that has a specific gene change called BRAF V600E. It is for those whose cancer has grown after at least one prior treatment and who have not had irinotecan stop working.
Guangzhou, GuangdongAges 18–75 - NCT07702032RecruitingPhase 3
Study of petosemtamab plus chemo for left-sided colorectal cancer
This trial tests a new drug (petosemtamab) plus standard chemo to see if it works better than the current standard (cetuximab plus chemo) for people with advanced left-sided colorectal cancer that has not been treated yet. It is for patients whose cancer cells have no RAS or BRAF mutations.
Manati, PRAges 18 years+ - NCT05379595RecruitingPhase 1/Phase 2
Amivantamab for advanced colon or rectal cancer with specific tumor traits
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
Birmingham, AlabamaAges 18 years+ - NCT07044908RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new drug called TQB2922 combined with TAS-102, with or without bevacizumab, for people whose advanced colorectal cancer has a normal RAS and BRAF gene and has not responded to standard chemotherapy. The goal is to see if this combination can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT07462143RecruitingPhase 2/Phase 3
New drug plus chemo for advanced colorectal cancer
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07604909RecruitingPhase 2
Serplulimab plus chemotherapy for early-relapsed colorectal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
ShanghaiAges 18 years+ - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT07221357RecruitingPhase 2/Phase 3
Pumitamig plus chemo vs standard care for new colorectal cancer
This trial tests a new drug called Pumitamig combined with chemotherapy against standard bevacizumab plus chemotherapy for people with advanced colorectal cancer that cannot be surgically removed and hasn't been treated yet. The goal is to see which combination works better and is safer.
Tucson, ArizonaAges 18 years+ - NCT06783569RecruitingPhase 1
First-in-human study for advanced solid tumors
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
Harbin, Heiljiang ProvinceAges 18 years+ - NCT07581912RecruitingPhase 2
Fulzerasib Plus Cetuximab for Advanced Colorectal Cancer With KRAS G12C
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
Hangzhou, ZhejiangAges 18–85 - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Montreal, QuebecAges 18–100 - NCT05954429RecruitingPhase 2
Study of fruquintinib plus immunotherapy after standard CRC treatment
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06434376Enrolling by invitationEarly Phase 1
Personalized immune therapy for ctDNA-positive colorectal cancer
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
Wenzhou, ZhejiangAges 18–80 - NCT04421820RecruitingPhase 1/Phase 2
BOLD-100 with chemo for advanced gut cancer
This Phase 1/2 study tests whether BOLD-100, given with the standard chemo combination FOLFOX, can help people with advanced gastrointestinal cancers. It’s especially focused on specific tumor features (including BRAF status) and checks safety, dosing, and early signs of effectiveness.
Santa Monica, CaliforniaAges 18 years+ - NCT05355701RecruitingPhase 1
Testing a new drug for advanced cancers with BRAF changes
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Fayetteville, ArkansasAges 16 years+ - NCT06848842RecruitingPhase 2
Ivonescimab and chemotherapy for colorectal cancer that spread only to the liver
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
BeijingAges 18 years+ - NCT07085091RecruitingPhase 1
Study of ALX2004 for advanced solid tumors
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Tampa, FloridaAges 18 years+ - NCT06958419RecruitingPhase 2/Phase 3
Short radiation plus targeted drugs for advanced colon cancer
This trial tests a combination of short-course radiation, chemotherapy, targeted therapy (bevacizumab), and an immunotherapy drug (PD-1 inhibitor) for people with advanced colorectal cancer that has spread and is not curable with surgery. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+
Hear when a new Colorectal Cancer (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (msi-h)?
- Yes. Clin2 currently lists 97 recruiting colorectal cancer (msi-h) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (msi-h) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (msi-h) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.